Global Ustekinumab Biosimilars Market Forecast 2026–2034: Growing at 8.7% CAGR to Reach USD 3.2 Billion

According to a new report from Intel Market Research, the global Ustekinumab Biosimilars market was valued at USD 1.5 billion in 2025 and is projected to reach USD 3.2 billion by 2034, growing at a CAGR of 8.7% during the forecast period (2026–2034). This substantial growth reflects increasing demand for cost-effective biologic alternatives to treat autoimmune disorders like psoriasis, Crohn's disease, and psoriatic arthritis.

What are Ustekinumab Biosimilars?

Ustekinumab biosimilars are biologic medications designed to replicate the therapeutic effects of the reference product Stelara®, which targets interleukin-12 and interleukin-23 to modulate immune responses. These biosimilars offer significant cost savings—often 20-30% lower than originator biologics—while maintaining comparable efficacy and safety profiles. By expanding patient access to advanced autoimmune therapies, biosimilars play a crucial role in healthcare cost containment strategies globally.

This report delivers comprehensive analysis of the Ustekinumab Biosimilars market landscape, covering everything from macro market trends to granular competitive intelligence. It examines key growth drivers, adoption barriers, regulatory pathways, and regional market dynamics that industry stakeholders need to navigate this evolving sector successfully.

For pharmaceutical executives, healthcare providers, and investors, these insights reveal where the market is heading and how to capitalize on emerging opportunities. The analysis also highlights strategic considerations for product development, market entry, and partnership formation in this competitive space.

📥 Download Sample Report: Ustekinumab Biosimilars Market - View in Detailed Research Report

Key Market Drivers

1. Rising Burden of Autoimmune Diseases
With over 125 million psoriasis patients worldwide and increasing incidence of inflammatory bowel diseases, the need for effective biologic therapies has never been greater. Ustekinumab's proven efficacy in treating these chronic conditions—achieving 75-90% skin clearance in psoriasis trials—creates strong underlying demand for biosimilar alternatives.

2. Patent Cliffs Creating Market Opportunities
The expiration of ustekinumab's key patents between 2024-2025 has opened the floodgates for biosimilar development. Over 15 biosimilar candidates are currently in various development phases, with first launches expected in major markets by 2026. These patent expiries could generate $3.8 billion in healthcare savings through increased competition and price erosion.

3. Healthcare Systems Prioritizing Biosimilar Adoption
Across Europe, 78% of hospitals have implemented biosimilar substitution policies for anti-TNF therapies, creating established pathways for ustekinumab biosimilar adoption. In the U.S., Medicare Part D redesign and commercial payer strategies are further accelerating biosimilar utilization to manage specialty drug costs.

Market Challenges

• High Development Costs: Bringing a biosimilar to market requires $100-250 million in development costs due to stringent analytical and clinical comparability requirements.

• Physician Hesitancy: 42% of specialists express reservations about switching stable patients from originator biologics without additional clinical data.

• Regulatory Complexity: While EMA and FDA have clear pathways, emerging markets often impose additional local clinical trial requirements that delay market entry.

Emerging Opportunities

The market presents several untapped opportunities:

• Therapeutic Expansion: Ongoing trials exploring ustekinumab's efficacy in pediatric psoriasis and ulcerative colitis could significantly expand the addressable patient population.

• Emerging Markets: Asia-Pacific represents the fastest-growing region with a projected 28% CAGR, driven by improving healthcare access and biosimilar-friendly policies in China, India, and Southeast Asia.

• Innovative Delivery Systems: Development of auto-injectors and other patient-friendly administration formats can differentiate biosimilars in competitive markets.

Regional Market Insights

• North America: Commands premium pricing and will likely adopt biosimilars through payer-driven switching programs following the first FDA approvals.

• Europe: Leads in biosimilar experience with established tender processes, but intense price competition creates margin pressure.

• Asia-Pacific: High-growth markets like China and India offer volume opportunities but require localized manufacturing partnerships.

• Latin America/Middle East: Emerging reimbursement frameworks and healthcare investments are making these regions increasingly viable for biosimilar commercialization.

Market Segmentation

By Application

• Plaque Psoriasis

• Psoriatic Arthritis

• Crohn's Disease

• Ulcerative Colitis

By End User

• Hospitals

• Specialty Clinics

• Retail Pharmacies

By Region

• North America

• Europe

• Asia-Pacific

• Latin America

• Middle East & Africa

📘 Get Full Report Here: Ustekinumab Biosimilars Market - View Detailed Research Report

Competitive Landscape

The Ustekinumab biosimilars market features both established pharmaceutical giants and specialized biosimilar developers:

• Teva Pharmaceuticals

• Samsung Bioepis

• Amgen

• Biocon Biologics

• Celltrion

• Sandoz (Novartis)

• Bio-Thera Solutions

• Other emerging players in Asia and Europe

Success in this market requires robust manufacturing capabilities, regulatory expertise, and commercial strategies tailored to different regional dynamics. Companies that can demonstrate therapeutic equivalence while offering competitive pricing and reliable supply will gain significant market share.

Report Deliverables

• Comprehensive market sizing and growth forecasts through 2034

• In-depth analysis of pipeline developments and regulatory landscapes

• Competitive intelligence on key players and their strategies

• Insights into pricing trends and reimbursement policies

• Detailed segmentation by indication, distribution channel, and geography

📥 Download Sample Report: Ustekinumab Biosimilars Market - View in Detailed Research Report

About Intel Market Research

Intel Market Research is a leading provider of strategic intelligence, offering actionable insights in biotechnology, pharmaceuticals, and healthcare infrastructure. Our research capabilities include:

• Real-time competitive benchmarking

• Global clinical trial pipeline monitoring

• Country-specific regulatory and pricing analysis

• Over 500+ healthcare reports annually

Trusted by Fortune 500 companies, our insights empower decision-makers to drive innovation with confidence.

🌐 Website: https://www.intelmarketresearch.com
📞 Asia-Pacific: +91 9169164321
🔗 LinkedIn: Follow Us